血清中性粒细胞明胶酶相关载脂蛋白（NGAL）在接受索非布韦治疗的埃及 HCV 阳性患者中的变化。
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
机构信息
Hepatology Department, National Liver Institute, Menoufia University, Shebin-Elkom, Egypt.
Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Shebin-Elkom, Egypt.
出版信息
Can J Gastroenterol Hepatol. 2020 Jan 27;2020:1632959. doi: 10.1155/2020/1632959. eCollection 2020.
BACKGROUND
Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen.
METHODS
This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done.
RESULTS
Our results showed a statistically significant decrease in serum NGAL (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (=0.02) with a nonsignificant reduction in eGFR (.
CONCLUSIONS
Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection.
背景
直接作用抗病毒药物（DAAs）彻底改变了 HCV 感染的治疗方式。索非布韦是一种高效的 DAA，主要通过肾脏清除。但在治疗过程中对肾脏安全性的担忧可能会限制其应用。中性粒细胞明胶酶相关脂质运载蛋白（NGAL）已被证明是肾小管损伤的预测因子。因此，本研究旨在评估 HCV 阳性患者在接受索非布韦为基础的抗病毒方案治疗前后血清中性粒细胞明胶酶相关脂质运载蛋白（NGAL）的变化。
方法
这是一项前瞻性研究，纳入了 87 例埃及慢性 HCV 感染患者，这些患者接受了索非布韦联合达拉他韦治疗，部分患者还联合了利巴韦林，疗程为 12 周。在治疗前和治疗结束时（EOT）检测血清 NGAL。分析 NGAL 和估算肾小球滤过率（eGFR）的变化。
结果
我们的结果显示，血清 NGAL 有统计学意义的下降（=0.02），而 eGFR 无显著下降（=0.02）。
结论
索非布韦似乎没有肾毒性作用，用于治疗慢性 HCV 感染患者是安全的。
Zotero 插件